Year Established: 1986
Revenues: $15,281 (+18%)
Net Income: $4,046 (+38%)
R&D: $5,673 (-4%)
TOP SELLING DRUGS
|Revlimid||multiple myeloma, mantle cell lymphoma||$9,685||18%|
|Abraxane||breast, lung, pancreatic cancer||$1,062||7%|
The year 2019 had barely begun when on January 3, BMS said it was paying roughly $74 billion to acquire Celgene, creating a top 10 company and a leading specialty biopharma in the areas of cancer, inflammatory and immunologic disease and cardiovascular disease.
The combined company offers leading oncology franchises in both solid tumors and hematologic malignancies with Opdivo and Yervoy as well as Revlimid and Pomalyst; a top five immunology and inflammation franchise with Orencia and Otezla; and the number one cardiovascular franchise led by Eliquis. The portfolio will include nine products with more than $1 billion in annual sales and significant potential for growth in the core disease areas of oncology, immunology and inflammation and cardiovascular disease.
When the news was announced, near-term launch opportunities included six expected product launches: two in immunology and inflammation, TYK2 and ozanimod; and four in hematology, luspatercept, liso-cel (JCAR017), bb2121 and fedratinib.
Together, the company will also have expanded capabilities in small molecule design, biologics/synthetic biologics, protein homeostasis, antibody engineering and cell therapy.
In 2018, growth was driven by strong product sales including Revlimid, $9.6 billion, up 18%; Pomalyst, $2 billion, up 26%; Otezla, $1.6 billion, up 26%; and Abraxane, $1 billion, up 7%.
Early in 2018, Celgene acquired Impact Biomedicines and its fedratinib for myelofibrosis and polycythemia vera, for $7 billion.
Celgene also plans to open a Research Incubator and Collaboration Center offering entrepreneurs lab space, resources and support to scientists and companies with potentially transformational approaches to accelerate medical innovations. Set to open this year, the facility houses 16,000 sq.-ft. of shared and fully equipped lab facilities on its campus in Summit, NJ.
Celgene formed several R&D partnerships, including a long-term discovery and development deal to identify new therapeutics in oncology with Evotec leveraging its preclinical discovery platform. This includes a phenotypic screening platform with unique compound libraries and associated target deconvolution capabilities. Celgene entered another discovery tie-up with Evotec in the field of targeted protein degradation that will leverage Evotec’s Panomics platform to identify drug targets that are traditionally difficult to track. The platform applies proteomics and transcriptomics at industrial scale to profile and select promising drug candidates based on cell profiles.